Targeting of Liposomes via PSGL1 for Enhanced Tumor Accumulation
To improve the delivery of liposomes to tumors using P-selectin glycoprotein ligand 1 (PSGL1) mediated binding to selectin molecules, which are upregulated on tumorassociated endothelium.
PSGL1 was orientated and presented on the surface of liposomes to achieve optimal selectin binding using a novel streptavidin-protein G linker molecule. Loading of PSGL1 liposomes with luciferin allowed their binding to e-selectin and activated HUVEC to be quantified in vitro and their stability, pharmacokinetics and tumor accumulation to be tested in vivo using murine models.
PSGL1 liposomes showed 5-fold (p < 0.05) greater selectin binding than identically formulated control liposomes modified with ligand that did not contain the selectin binding domain. When added to HUVEC, PSGL1 liposomes showed >7-fold (p < 0.001) greater attachment than control liposomes. In in vivo studies PSGL1 liposomes showed similar stability and circulation to control liposomes but demonstrated a >3-fold enhancement in the level of delivery to tumors (p < 0.05).
The technologies and strategies described here may contribute to clinical improvements in the selectivity and efficacy of liposomal drug delivery agents.
- Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189–207. CrossRef
- Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10:417–27. CrossRef
- Laginha KM, Verwoert S, Charrois GJ, Allen TM. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res. 2005;11:6944–9. CrossRef
- Magzoub M, Jin S, Verkman AS. Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. FASEB J. 2008;22:276–84. CrossRef
- Tailor TD, Hanna G, Yarmolenko PS, Dreher MR, Betof AS, Nixon AB, et al. Effect of pazopanib on tumor microenvironment and liposome delivery. Mol Cancer Ther. 2010;9:1798–808. CrossRef
- Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 2009;78:539–52. CrossRef
- Fox SB, Gatter KC, Altman DG, Leek RD, Harris AL. Re: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst. 1995;87:1798–9. author reply 1801–1792. CrossRef
- Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer. 2002;2:83–90. CrossRef
- Sedlacek HH. Pharmacological aspects of targeting cancer gene therapy to endothelial cells. Crit Rev Oncol Hematol. 2001;37:169–215. CrossRef
- Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res. 2004;10:7965–71. CrossRef
- Fox SB, Turner GD, Leek RD, Whitehouse RM, Gatter KC, Harris AL. The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumor endothelium. Breast Cancer Res Treat. 1995;36:219–26. CrossRef
- Denton KJ, Stretch JR, Gatter KC, Harris AL. A study of adhesion molecules as markers of progression in malignant melanoma. J Pathol. 1992;167:187–91. CrossRef
- Mayer B, Spatz H, Funke I, Johnson JP, Schildberg FW. De novo expression of the cell adhesion molecule E-selectin on gastric cancer endothelium. Langenbecks Arch Surg. 1998;383:81–6. CrossRef
- Zocchi MR, Poggi A. Lymphocyte-endothelial cell adhesion molecules at the primary tumor site in human lung and renal cell carcinomas. J Natl Cancer Inst. 1993;85:246–7. CrossRef
- Norman KE, Katopodis AG, Thoma G, Kolbinger F, Hicks AE, Cotter MJ, et al. P-selectin glycoprotein ligand-1 supports rolling on E- and P-selectin in vivo. Blood. 2000;96:3585–91.
- Zarbock A, Ley K, McEver RP, Hidalgo A. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood. 2011;118:6743–51. CrossRef
- Bachtarzi H, Stevenson M, Subr V, Ulbrich K, Seymour LW, Fisher KD. Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins. J Control Release. 2011;150:196–203. CrossRef
- Korokhov N, Mikheeva G, Krendelshchikov A, Belousova N, Simonenko V, Krendelshchikova V, et al. Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J Virol. 2003;77:12931–40. CrossRef
- Willemsen RA, Pechar M, Carlisle RC, Schooten E, Pola R, Thompson AJ, et al. Multi-component polymeric system for tumour cell-specific gene delivery using a universal bungarotoxin linker. Pharm Res. 2010;27:2274–82. CrossRef
- Carlisle RC, Benjamin R, Briggs SS, Sumner-Jones S, McIntosh J, Gill D, et al. Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera. J Gene Med. 2008;10:400–11. CrossRef
- Hensley P, McDevitt PJ, Brooks I, Trill JJ, Feild JA, McNulty DE, et al. The soluble form of E-selectin is an asymmetric monomer. Expression, purification, and characterization of the recombinant protein. J Biol Chem. 1994;269:23949–58.
- Ogawara K, Rots MG, Kok RJ, Moorlag HE, Van Loenen AM, Meijer DK, et al. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther. 2004;15:433–43. CrossRef
- Lievens J, Snoeys J, Vekemans K, Van Linthout S, de Zanger R, Collen D, et al. The size of sinusoidal fenestrae is a critical determinant of hepatocyte transduction after adenoviral gene transfer. Gene Ther. 2004;11:1523–31. CrossRef
- Wisse E, Jacobs F, Topal B, Frederik P, De Geest B. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther. 2008;15:1193–9. CrossRef
- Gunawan RC, Almeda D, Auguste DT. Complementary targeting of liposomes to IL-1alpha and TNF-alpha activated endothelial cells via the transient expression of VCAM1 and E-selectin. Biomaterials. 2011;32:9848–53. CrossRef
- Liu Q, Zaiss AK, Colarusso P, Patel K, Haljan G, Wickham TJ, et al. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther. 2003;14:627–43. CrossRef
- Kheirolomoom A, Kruse DE, Qin S, Watson KE, Lai CY, Young LJ, et al. Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system. J Control Release. 2010;141:128–36. CrossRef
- Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009;71:409–19. CrossRef
- Kleiter MM, Yu D, Mohammadian LA, Niehaus N, Spasojevic I, Sanders L, et al. A tracer dose of technetium-99m-labeled liposomes can estimate the effect of hyperthermia on intratumoral doxil extravasation. Clin Cancer Res. 2006;12:6800–7. CrossRef
- Soundararajan A, Bao A, Phillips WT, Perez 3rd R. Goins BA. [(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nucl Med Biol. 2009;36:515–24. CrossRef
- Iyer AK, Su Y, Feng J, Lan X, Zhu X, Liu Y, et al. The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma. Biomaterials. 2011;32:2605–13. CrossRef
- Ogawara K, Un K, Minato K, Tanaka K, Higaki K, Kimura T. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors. Int J Pharm. 2008;359:234–40. CrossRef
- Molema G. Tumor vasculature directed drug targeting: applying new technologies and knowledge to the development of clinically relevant therapies. Pharm Res. 2002;19:1251–8. CrossRef
- Spragg DD, Alford DR, Greferath R, Larsen CE, Lee KD, Gurtner GC, et al. Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc Natl Acad Sci USA. 1997;94:8795–800. CrossRef
- Stahn R, Grittner C, Zeisig R, Karsten U, Felix SB, Wenzel K. Sialyl Lewis(x)-liposomes as vehicles for site-directed, E-selectin-mediated drug transfer into activated endothelial cells. Cell Mol Life Sci. 2001;58:141–7. CrossRef
- Bruehl RE, Dasgupta F, Katsumoto TR, Tan JH, Bertozzi CR, Spevak W, et al. Polymerized liposome assemblies: bifunctional macromolecular selectin inhibitors mimicking physiological selectin ligands. Biochemistry. 2001;40:5964–74. CrossRef
- Bachtarzi H, Stevenson M, Subr V, Seymour LW, Fisher KD. E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-alpha-activated human umbilical vein endothelial cells. J Drug Target. 2011;19:690–700. CrossRef
- Gallizia A, de Lalla C, Nardone E, Santambrogio P, Brandazza A, Sidoli A, et al. Production of a soluble and functional recombinant streptavidin in Escherichia coli. Protein Expr Purif. 1998;14:192–6. CrossRef
- Green NM. Avidin and streptavidin. Methods Enzymol. 1990;184:51–67. CrossRef
- Matsumoto T, Takase R, Tanaka T, Fukuda H, Kondo A. Site-specific protein labeling with amine-containing molecules using Lactobacillus plantarum sortase. Biotechnol J. 2011.
- Deckers R, Moonen CT. Ultrasound triggered, image guided, local drug delivery. J Control Release. 2010;148:25–33. CrossRef
- Brujan EA, Ikeda T, Matsumoto Y. Jet formation and shock wave emission during collapse of ultrasound-induced cavitation bubbles and their role in the therapeutic applications of high-intensity focused ultrasound. Phys Med Biol. 2005;50:4797–809. CrossRef
- Targeting of Liposomes via PSGL1 for Enhanced Tumor Accumulation
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Volume 30, Issue 2 , pp 352-361
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- drug delivery
- Industry Sectors